- Home
- NEWP vs CBIO Comparison
NEWP vs CBIO Comparison
Compare NEWP & CBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEWP
- CBIO
- Stock Information
- Founded
- NEWP 1972
- CBIO 2003
- Country
- NEWP Canada
- CBIO United States
- Employees
- NEWP N/A
- CBIO N/A
- Industry
- NEWP
- CBIO
- Sector
- NEWP
- CBIO
- Exchange
- NEWP Nasdaq
- CBIO Nasdaq
- Market Cap
- NEWP 259.4M
- CBIO 308.0M
- IPO Year
- NEWP N/A
- CBIO N/A
- Fundamental
- Price
- NEWP $1.45
- CBIO $12.00
- Analyst Decision
- NEWP
- CBIO Strong Buy
- Analyst Count
- NEWP 0
- CBIO 3
- Target Price
- NEWP N/A
- CBIO $25.67
- AVG Volume (30 Days)
- NEWP 287.8K
- CBIO 132.4K
- Earning Date
- NEWP 09-23-2025
- CBIO 07-31-2025
- Dividend Yield
- NEWP N/A
- CBIO N/A
- EPS Growth
- NEWP N/A
- CBIO N/A
- EPS
- NEWP N/A
- CBIO N/A
- Revenue
- NEWP N/A
- CBIO N/A
- Revenue This Year
- NEWP N/A
- CBIO N/A
- Revenue Next Year
- NEWP N/A
- CBIO N/A
- P/E Ratio
- NEWP N/A
- CBIO N/A
- Revenue Growth
- NEWP N/A
- CBIO N/A
- 52 Week Low
- NEWP $0.93
- CBIO $11.06
- 52 Week High
- NEWP $2.05
- CBIO $21.40
- Technical
- Relative Strength Index (RSI)
- NEWP 39.89
- CBIO N/A
- Support Level
- NEWP $1.61
- CBIO N/A
- Resistance Level
- NEWP $1.71
- CBIO N/A
- Average True Range (ATR)
- NEWP 0.10
- CBIO 0.00
- MACD
- NEWP -0.04
- CBIO 0.00
- Stochastic Oscillator
- NEWP 13.18
- CBIO 0.00
About NEWP New Pacific Metals Corp.
New Pacific Metals Corp is a Canadian Mining Issuer, in the business of exploring and developing precious metal properties in Bolivia. The company's projects which are also its reportable segments include Silver Sand; Carangas and Silverstrike.
About CBIO Crescent Biopharma Inc. Common Stock
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.